RVL Pharmaceuticals plc

Good day, everyone. My name is Chelsea, and I'll be your conference operator. At this time, I'd like to welcome everyone to the RVL Pharmaceuticals third quarter 2022 financial results call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer period. At that time, if you have a question, please press star 1 on your telephone keypad, As a reminder, this conference call is being recorded today, November 10th, 2022. It is now my pleasure to turn the floor over to Ms. Lisa Wilson, Investor Relations for RVL Pharmaceuticals. Please go ahead.

Thank you, operator. Welcome to RVL Pharmaceuticals' third quarter 2022 financial results and commercial update call. This is Lisa Wilson, Investor Relations for RVL. With me on today's call are RVL's Chief Executive Officer, Brian Markison, Chief Operating Officer, J.D. Schaub, and Interim Chief Financial Officer, Mike DiPietro. This afternoon, the company issued a press release detailing financial results for the three months ended September 30th, 2022. This press release and a webcast of this call can be accessed through the investor section of the RVL website at rvlpharma.com. Before we get started, I would like to remind everyone that any statements made on today's conference call that express a belief, expectation, projection, forecast, anticipation, or intent regarding future events and the company's future performance may be considered forward-looking statements as defined by the Private Securities Litigation Reform Act. These forward-looking statements are based on information available to management as of today and involve risks and uncertainties, including those noted in this afternoon's press release and the company's filings with the Securities and Exchange Commission. Such forward-looking statements are not guarantees of future performance. Actual results may differ materially from those projected in the forward-looking statements. RVL specifically disclaims any intent or obligation to update these four liquid statements except as required by law. During this call, we refer to non-GAAP financial measures such as adjusted EBITDA. For reconciliation of adjusted EBITDA to net income or loss from continuing operations, please see the tables at the end of today's press release. The archived webcast of this call will be available for one year on RVL's website, rvlpharma.com. For the benefit of those who may be listening to the Replay or Archive webcast, this call was held and recorded on Thursday, November 10th, 2022. Since then, RVL may have made announcements related to the topics discussed, so please reference the company's most recent press releases and SEC filings. And with that, I'll turn the call over to RVL CEO, Brian Markison.

Brian Markison Good afternoon, and thank you for joining our call. The third quarter for RVL was particularly noteworthy. First, we grew 19% Q3 22 over Q2 22, highlighting meaningful sequential growth in the face of challenging macros or headwinds. Second, in August, we substantially strengthened our balance sheet with an insider led financing at the market. Third, as of the end of October, we had opened approximately 3,800 points of sale in aesthetics, and roughly 1,100 of those locations have reordered APNIC at least once. This is excellent traction, especially since our launch into medical aesthetics is only 10 months young. APNIC is a disruptive technology that is unique in the marketplace and is the centerpiece of our strategy to be a leading growth company in medical aesthetics. Fourth, we have filled out our aesthetic sales team and now have a full complement of approximately 75 territory managers. Of particular note is the exceptional quality of this team and the management core that we have attracted. In many respects, it is testimony to the great asset we have and the opportunity in front of us. Fifth, we plan to launch our new e-commerce platform in the first quarter of 23. This will simplify all of our customer interactions and, most importantly, introduce a tailored subscription plan that will enhance our connectivity to our patients and drive reorders or refills. Finally, our global partner, Santan, has continued to advance development around the world. Santana's commenced the required registrational trial in Japan and plans to begin the same in China next year. Now, I'd like to turn the call over to Mike.